Here's a wire summary -- but clearly good news for Kenilworth:
. . . .Merck announced an agreement Thursday to buy Pandion Therapeutics Inc. in a deal valued at $1.85 billion. Under terms of the deal, Merck will pay $60 in cash for each Pandion share outstanding, which represents a 134.1% premium to Wednesday's closing price.
Pandion is a biotechnology company which uses its TALON technology to develop autoimmune treatments. The deal is expected to close in the first half of 2021. Merck shares rose 0.6% in premarket trading, while Pandion's stock was still untraded. . . .
Onward. . . rushing. Kinda' a busy day -- on the billable side. . . . grinning. [Updated: Gratifying to see Cy Vance's team of forensic accountants and financial crimes prosecutors have the millions of pages now, in the shop. Just time and tide now, love -- time, and tide. . . Quite a sunny day, for America. . . .]
नमस्ते
